GlassScriptPhysician profile
Carlos Alberto Taboada
NPI 1174565089
$10,338.32
in general payments reported to CMS, 2019-2025
59 companies · $4,867 in 2025
The $4,867 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $316 · 2021: $685 · 2022: $1,513 · 2023: $1,164 · 2024: $896 · 2025: $4,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,012 · Travel and Lodging: $1,718 · Long Term Medical Supply Or Device Loan: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,011.87 |
| Travel and Lodging | $1,717.69 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $2,287.47 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,688.17 | 2023-2025 | |
| Celgene Corporation | $625.51 | 2022-2024 | Pomalyst, Opdualag |
| Ethicon US, LLC | $603.29 | 2021-2023 | Echelon; Endopath, Echelon Circular, Vistaseal |
| Janssen Biotech, INC. | $408.04 | 2022-2025 | Tecvayli, Talvey, Darzalex |
| Gilead Sciences, INC. | $357.92 | 2021-2025 | Trodelvy |
| Davol INC. | $302.28 | 2019-2025 | Arista |
| Abbvie INC. | $286.40 | 2019-2025 | Venclexta |
| Exelixis INC. | $282.39 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $241.68 | 2023-2024 | Exparel |
| Merck Sharp & Dohme LLC | $204.93 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $153.98 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Sirtex Medical INC | $151.68 | 2022-2023 | Sir-Spheres Microspheres |
| Biom'Up France Sas | $148.82 | 2021 | |
| Daiichi Sankyo INC. | $148.32 | 2021-2025 | Enhertu, Datroway |
Show all 55 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Taboada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.